Oncocyte Corp Stock Alpha and Beta Analysis
| OCX Stock | USD 2.44 0.09 3.56% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as OncoCyte Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in OncoCyte Corp over a specified time horizon. Remember, high OncoCyte Corp's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to OncoCyte Corp's market risk premium analysis include:
Beta 0.54 | Alpha (0.41) | Risk 3.14 | Sharpe Ratio (0.10) | Expected Return (0.33) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
OncoCyte |
OncoCyte Corp Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. OncoCyte Corp market risk premium is the additional return an investor will receive from holding OncoCyte Corp long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in OncoCyte Corp. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate OncoCyte Corp's performance over market.| α | -0.41 | β | 0.54 |
OncoCyte Corp expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of OncoCyte Corp's Buy-and-hold return. Our buy-and-hold chart shows how OncoCyte Corp performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.OncoCyte Corp Market Price Analysis
Market price analysis indicators help investors to evaluate how OncoCyte Corp stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading OncoCyte Corp shares will generate the highest return on investment. By understating and applying OncoCyte Corp stock market price indicators, traders can identify OncoCyte Corp position entry and exit signals to maximize returns.
OncoCyte Corp Return and Market Media
The median price of OncoCyte Corp for the period between Sun, Sep 1, 2024 and Sat, Nov 30, 2024 is 3.04 with a coefficient of variation of 6.11. The daily time series for the period is distributed with a sample standard deviation of 0.18, arithmetic mean of 2.98, and mean deviation of 0.14. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Ronald Andrews of 40000 shares of OncoCyte Corp at 0.96 subject to Rule 16b-3 | 09/23/2024 |
2 | Acquisition by Gisela Paulsen of 350000 shares of OncoCyte Corp subject to Rule 16b-3 | 09/27/2024 |
3 | Acquisition by Broadwood Partners, L.p. of 13153 shares of OncoCyte Corp at 2.948 subject to Rule 16b-3 | 10/02/2024 |
4 | Oncocyte gains 6 percent on 10.2M private placement | 10/03/2024 |
5 | OncoCyte Corp Q2 2024 Earnings Call Highlights Strategic Advances Amidst Financial Challenges | 10/09/2024 |
6 | Acquisition by Andrea James of 100000 shares of OncoCyte Corp subject to Rule 16b-3 | 10/11/2024 |
7 | Acquisition by Andrea James of 200000 shares of OncoCyte Corp at 2.87 subject to Rule 16b-3 | 10/15/2024 |
8 | OncoCyte files for secondary stock offering | 10/16/2024 |
9 | OncoCyte Coverage Initiated at StockNews.com | 10/25/2024 |
10 | Disposition of 3564728 shares by Gutfreund John Peter of OncoCyte Corp at 1.53 subject to Rule 16b-3 | 11/05/2024 |
11 | Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 | 11/06/2024 |
12 | OncoCyte Corp Q3 2024 Earnings EPS of -0. ... | 11/12/2024 |
13 | Earnings call OncoCyte outlines growth strategy in Q3 2024 earnings | 11/13/2024 |
14 | StockNews.com Initiates Coverage on OncoCyte | 11/15/2024 |
About OncoCyte Corp Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including OncoCyte or other stocks. Alpha measures the amount that position in OncoCyte Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 0.001654 | 0.00147 | Price To Sales Ratio | 12.73 | 12.09 |
OncoCyte Corp Upcoming Company Events
As portrayed in its financial statements, the presentation of OncoCyte Corp's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, OncoCyte Corp's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of OncoCyte Corp's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of OncoCyte Corp. Please utilize our Beneish M Score to check the likelihood of OncoCyte Corp's management manipulating its earnings.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with OncoCyte Corp
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.